In vivo, MIRX34 increased the number of tumor infiltrating CD8+ T-cells and decreased the number of exhausted CD8+PD1+ T-cells and macrophages, suggesting that miR-34 may have a direct effect on immune evasion that can be exploited therapeutically. The gene discussed is PDCD1; the disease is neoplasm.